{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:53:37Z","timestamp":1790787217027,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-111-2314-B-037-042"],"award-info":[{"award-number":["NSTC-111-2314-B-037-042"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-112-2221-E-020-005"],"award-info":[{"award-number":["NSTC-112-2221-E-020-005"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-113-2314-B-037-076-MY3"],"award-info":[{"award-number":["NSTC-113-2314-B-037-076-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40259-025-00705-5","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T21:02:23Z","timestamp":1738098143000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-458X","authenticated-orcid":false,"given":"Sebastian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-1700","authenticated-orcid":false,"given":"An-Ping","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"4","key":"705_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2023.06.028","volume":"89","author":"MM Tran","year":"2023","unstructured":"Tran MM, Moseley IH, George EA, Qureshi AA, Cho E. Examining the burden of psoriasis and psoriatic arthritis in a US adult cohort using the All of Us Research Program. J Am Acad Dermatol. 2023;89(4):859\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"705_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-022-02617-5","volume":"20","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. Bmc Med. 2022;20(1):421.","journal-title":"Bmc Med"},{"issue":"16","key":"705_CR3","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.3390\/ijms23169063","volume":"23","author":"S Piaserico","year":"2022","unstructured":"Piaserico S, Orlando G, Messina F. Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci. 2022;23(16):9063.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"705_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797\u2013806.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"705_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/ds.ds_55_20","volume":"39","author":"S-F Yang","year":"2021","unstructured":"Yang S-F, Chen T-H, Tsai S-H, Chen P-E, Chi C-C, Tung T-H. Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: a systematic review and meta-analysis of cohort studies. Dermatol Sin. 2021;39(1):19.","journal-title":"Dermatol Sin"},{"issue":"7","key":"705_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s11255-018-1868-z","volume":"50","author":"P Ungprasert","year":"2018","unstructured":"Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277\u201383.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"705_CR7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/1346-8138.16941","volume":"50","author":"M Chu","year":"2023","unstructured":"Chu M, Shen S, Zhu Z, Li Z, Bai Y, Ma J, et al. Association of psoriasis with depression, anxiety, and suicidality: a bidirectional two-sample Mendelian randomization study. J Dermatol. 2023;50(12):1629\u201334.","journal-title":"J Dermatol"},{"issue":"9","key":"705_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jdv.14303","volume":"31","author":"S Yu","year":"2017","unstructured":"Yu S, Yu CL, Huang YC, Tu HP, Lan CE. Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2017;31(9):1497\u2013504.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"705_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dsi.2016.07.005","volume":"35","author":"H-P Tu","year":"2017","unstructured":"Tu H-P, Yu C-L, Lan C-CE, Yu S. Prevalence of schizophrenia in patients with psoriasis: a nationwide study. Dermatol Sin. 2017;35(1):1\u20136.","journal-title":"Dermatol Sin"},{"issue":"5","key":"705_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","volume":"59","author":"S AlQassimi","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis\u2013comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566\u201371.","journal-title":"Int J Dermatol"},{"issue":"1","key":"705_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13555-022-00832-9","volume":"13","author":"JJ Wu","year":"2023","unstructured":"Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13(1):207\u201319.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"12","key":"705_CR12","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1007\/s13555-023-01062-3","volume":"13","author":"HT Nguyen","year":"2023","unstructured":"Nguyen HT, Vu AT, Pham NTU, Tran TNA, Pham NN, Bui HTT, et al. Comorbidity burden and treatment patterns of psoriasis in vietnam: real-world data from the EXPAND Study. Dermatol Ther (Heidelb). 2023;13(12):3193\u2013208.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"705_CR13","first-page":"874","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874\u201388.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"705_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/acr.22492","volume":"67","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(5):708\u201317.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"12","key":"705_CR15","doi-asserted-by":"publisher","first-page":"e1388","DOI":"10.1111\/jdv.19334","volume":"37","author":"S Yu","year":"2023","unstructured":"Yu S, Wei JC. Regarding Mastorino et al.\u2019s \u201cEfficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.\u201d J Eur Acad Dermatol Venereol. 2023;37(12):e1388\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"705_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","volume":"109","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci. 2023;109(1):12\u201321.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"705_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdermsci.2022.08.004","volume":"107","author":"P Vacharanukrauh","year":"2022","unstructured":"Vacharanukrauh P, Meephansan J, Ponnikorn S, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, et al. Transcriptome profiling in psoriasis: NB-UVB treatment-associated transcriptional changes and modulation of autoinflammation in perilesional skin in early-phase disease. J Dermatol Sci. 2022;107(3):123\u201332.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"705_CR18","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ramirez J, Canete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901.","journal-title":"Int J Mol Sci"},{"issue":"10201","key":"705_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"9","key":"705_CR20","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/jdv.19135","volume":"37","author":"L Mastorino","year":"2023","unstructured":"Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, et al. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J Eur Acad Dermatol Venereol. 2023;37(9):1848\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"705_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"705_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","volume":"11","author":"A Watad","year":"2024","unstructured":"Watad A, Zabotti A, Patt YS, Gendelman O, Dotan A, Ben-Shabat N, et al. From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11(4):963\u201376.","journal-title":"Rheumatol Ther."},{"issue":"9","key":"705_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"705_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003143","volume":"9","author":"G De Marco","year":"2023","unstructured":"De Marco G, Zabotti A, Baraliakos X, Iagnocco A, Aletaha D, Gisondi P, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023;9(2): e003143.","journal-title":"RMD Open"},{"issue":"4","key":"705_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","volume":"71","author":"X Huang","year":"2023","unstructured":"Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71(4):505\u201315.","journal-title":"Immunol Res"},{"issue":"12","key":"705_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063650","volume":"12","author":"RH Haberman","year":"2022","unstructured":"Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12): e063650.","journal-title":"BMJ Open"},{"issue":"5","key":"705_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/1756-185X.14663","volume":"26","author":"T Ak","year":"2023","unstructured":"Ak T, Temiz SNY, Taner M, Ayla AY, Aygun AA, Engin B, et al. Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study. Int J Rheum Dis. 2023;26(5):878\u201384.","journal-title":"Int J Rheum Dis"},{"key":"705_CR28","first-page":"2023","volume":"19","author":"G Caldarola","year":"2023","unstructured":"Caldarola G, De Luca E, Bavetta M, Bernardini N, Dattola A, De Simone C, et al. 2-Year experience with risankizumab in the treatment of plaque psoriasis in Lazio region, Italy. Dermatol Ther. 2023;19:2023.","journal-title":"Dermatol Ther"},{"issue":"4","key":"705_CR29","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","volume":"5","author":"S Singla","year":"2023","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200\u20137.","journal-title":"Lancet Rheumatol."},{"issue":"6","key":"705_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578","volume":"7","author":"FS Yen","year":"2024","unstructured":"Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024;7(6): e2416578.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"705_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-024-03331-0","volume":"22","author":"WJ Wang","year":"2024","unstructured":"Wang WJ, Wang YH, Huang CH, Hsieh TH, Ibarburu GH, Wei JCC. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. Bmc Med. 2024;22(1):117.","journal-title":"Bmc Med"},{"key":"705_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115970","volume":"337","author":"RY Tsai","year":"2024","unstructured":"Tsai RY, Gau SY, Ho YJ, Lin SY, Ku CY, Wang SI, et al. Long-COVID impacts taste and olfactory in individuals with substance use disorder: a retrospective cohort study from the TriNetX US Collaborative Networks. Psychiatry Res. 2024;337: 115970.","journal-title":"Psychiatry Res"},{"issue":"9","key":"705_CR33","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/1756-185X.14833","volume":"26","author":"YP Loo","year":"2023","unstructured":"Loo YP, Loo CH, Lim AL, Wong CK, Ali NBM, Khor YH, et al. Prevalence and risk factors associated with psoriatic arthritis among patients with psoriasis. Int J Rheum Dis. 2023;26(9):1788\u201398.","journal-title":"Int J Rheum Dis"},{"key":"705_CR34","doi-asserted-by":"crossref","unstructured":"Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12-S21.","DOI":"10.1002\/msc.1694"},{"key":"705_CR35","doi-asserted-by":"crossref","unstructured":"Yu S, Lee CW, Li YA, Chen TH, HS Y. Prenatal infection predisposes offspring to enhanced susceptibility to imiquimod-mediated psoriasiform dermatitis in mice. Dermatol Sin. 2022;40(1):14-9.","DOI":"10.4103\/ds.ds_6_22"},{"issue":"11","key":"705_CR36","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/jdv.20143","volume":"38","author":"A Chiricozzi","year":"2024","unstructured":"Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. J Eur Acad Dermatol Venereol. 2024;38(11):2175\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"705_CR37","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1038\/s41598-020-65269-6","volume":"10","author":"L Chen","year":"2020","unstructured":"Chen L, Deshpande M, Grisotto M, Smaldini P, Garcia R, He Z, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10(1):8259.","journal-title":"Sci Rep"},{"issue":"1","key":"705_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/annrheumdis-2021-221255","volume":"81","author":"DG McGonagle","year":"2022","unstructured":"McGonagle DG, Zabotti A, Watad A, Bridgewood C, De Marco G, Kerschbaumer A, et al. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Ann Rheum Dis. 2022;81(1):7\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"705_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/1756-185X.14603","volume":"26","author":"R Cai","year":"2023","unstructured":"Cai R, Jin Y, Chen B, Zhao J, Zhai J, Zeng L, et al. Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: a systematic review and aggregate data meta-analysis of randomized controlled trials. Int J Rheum Dis. 2023;26(4):625\u201337.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"705_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40265-024-02026-3","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie T, Shirley M. Bimekizumab: a review in psoriatic arthritis. Drugs. 2024;84(5):587\u201398.","journal-title":"Drugs"},{"issue":"3","key":"705_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41590-024-01755-7","volume":"25","author":"T Wertheimer","year":"2024","unstructured":"Wertheimer T, Zwicky P, Rindlisbacher L, Sparano C, Vermeer M, de Melo BMS, et al. IL-23 stabilizes an effector T(reg) cell program in the tumor microenvironment. Nat Immunol. 2024;25(3):512\u201324.","journal-title":"Nat Immunol"},{"key":"705_CR42","doi-asserted-by":"publisher","first-page":"1276743","DOI":"10.3389\/fonc.2023.1276743","volume":"13","author":"J Jacobse","year":"2023","unstructured":"Jacobse J, Pilat JM, Li J, Brown RE, Kwag A, Buendia MA, et al. Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis. Front Oncol. 2023;13:1276743.","journal-title":"Front Oncol"},{"issue":"7","key":"705_CR43","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, et al. Differential changes in inflammatory mononuclear phagocyte and t-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707\u201318.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"705_CR44","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","volume":"73","author":"EF Leijten","year":"2021","unstructured":"Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 2021;73(7):1220\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"705_CR45","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891\u2013904.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"705_CR46","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.3390\/jcm12072701","volume":"12","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023;12(7):2701.","journal-title":"J Clin Med"},{"issue":"6","key":"705_CR47","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/genes14061297","volume":"14","author":"SF Yang","year":"2023","unstructured":"Yang SF, Lin MH, Chou PC, Hu SK, Shih SY, Yu HS, et al. Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics. Genes (Basel). 2023;14(6):1297.","journal-title":"Genes (Basel)."},{"key":"705_CR48","doi-asserted-by":"crossref","unstructured":"Yu S, Tsao YH, Tu HP, CCE L. Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. Dermatol Sin. 2022;40(1):20-7.","DOI":"10.4103\/ds.ds_8_22"},{"issue":"2","key":"705_CR49","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1111\/jdv.19517","volume":"38","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients\u2019-response to Yu et al. J Eur Acad Dermatol Venereol. 2024;38(2):e175\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"705_CR50","doi-asserted-by":"publisher","first-page":"1385491","DOI":"10.3389\/fmed.2024.1385491","volume":"11","author":"B Gershater","year":"2024","unstructured":"Gershater B, Bieber K, Vorobyev A, Ludwig MA, Zirpel H, De Luca DA, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis. Front Med (Lausanne). 2024;11:1385491.","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"705_CR51","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/1756-185X.14805","volume":"26","author":"C Lu","year":"2023","unstructured":"Lu C, Yang F, Liu H, Dou L, Wang Y, Li H, et al. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1737\u201344.","journal-title":"Int J Rheum Dis"},{"issue":"6 Suppl 1","key":"705_CR52","first-page":"48","volume":"49","author":"J Takeshita","year":"2022","unstructured":"Takeshita J, Chau J, Duffin KC, Goel N. Promoting diversity, equity, and inclusion for psoriatic diseases. J Rheumatol. 2022;49(6 Suppl 1):48\u201351.","journal-title":"J Rheumatol"},{"issue":"11","key":"705_CR53","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","volume":"12","author":"G Yadav","year":"2022","unstructured":"Yadav G, Yeung J, Miller-Monthrope Y, Lakhani O, Drudge C, Craigie S, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther (Heidelb). 2022;12(11):2401\u201313.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"705_CR54","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jaad.2022.03.067","volume":"87","author":"S McKenzie","year":"2022","unstructured":"McKenzie S, Brown-Korsah JB, Syder NC, Omar D, Taylor SC, Elbuluk N. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"705_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/24755303231198482","volume":"9","author":"H Peterson","year":"2024","unstructured":"Peterson H, Huang MY, Lee K, Kingston P, Yee D, Korouri E, et al. Comorbidity burden in psoriasis patients with skin of color. J Psoriasis Psoriatic Arthritis. 2024;9(1):16\u201322.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"issue":"2","key":"705_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004314","volume":"10","author":"A Zabotti","year":"2024","unstructured":"Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10(2): e004314.","journal-title":"RMD Open"},{"issue":"1","key":"705_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-023-01072-1","volume":"14","author":"E Errichetti","year":"2024","unstructured":"Errichetti E, Zabotti A. Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors. Dermatol Ther (Heidelb). 2024;14(1):1\u20133.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"705_CR58","doi-asserted-by":"crossref","unstructured":"Floris A, Mugheddu C, Sichi L, Anedda J, Frau A, Sorgia J, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024; p. keae257 (ahead of print).","DOI":"10.1093\/rheumatology\/keae257"},{"issue":"9","key":"705_CR59","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/1756-185X.14667","volume":"26","author":"RB Ozince","year":"2023","unstructured":"Ozince RB, Ak T, Erzin YZ, Melikoglu M, Seyahi E. Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1811\u20135.","journal-title":"Int J Rheum Dis"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00705-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:18:16Z","timestamp":1741835896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00705-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00705-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"12 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by a grant from the Taiwan National Science and Technology Council (NSTC-111-2314-B-037-042, NSTC-112-2221-E-020-005, and NSTC-113-2314-B-037-076-MY3) to S.Y.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest Statement"}},{"value":"TriNetX obtained a waiver from the Western Institutional Review Board (WIRB) due to its provision of aggregated counts and statistical summaries of de-identified data, adhering to the de-identification standards specified in Section \u00a7164.514(a) of the HIPAA Privacy Rule. This study was approved by Chung Shan Medical University Hospital Institutional Review Board (IRB NO: CS2-21176).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Ethics Approval, Human Participants"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability Statement"}},{"value":"Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and Public Involvement Statement"}},{"value":"Conceptualization:\n                      Sebastian Yu, An-Ping Huo, James Cheng-Chung Wei.\n                      Methodology:\n                      Sebastian Yu, Yu-Hsun Wang, James Cheng-Chung Wei.\n                      Formal analysis and investigation:\n                      Sebastian Yu, Yu-Hsun Wang, James Cheng-Chung Wei.\n                      Writing\n                      \u2013\n                      original draft preparation:\n                      Sebastian Yu, An-Ping Huo.\n                      Writing - review and editing:\n                      Yu-Hsun Wang, James Cheng-Chung Wei.\n                      Funding acquisition:\n                      Sebastian Yu, James Cheng-Chung Wei.\n                      Resources:\n                      James Cheng-Chung Wei.\n                      Supervision:\n                      James Cheng-Chung Wei.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}